Dr. Camille Ragin is Professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center-Temple University Health System in Philadelphia. Her research focuses on cancer epidemiology and prevention primarily in Black populations. She earned a Ph.D. in Infectious Diseases and Microbiology from the University of Pittsburgh, Graduate School of Public Health and completed her postdoctoral training and MPH degree in Epidemiology as part of the NIH/NCI-funded Cancer Education and Career Development Program at the University of Pittsburgh Cancer Institute. Her research focuses on the molecular epidemiology of Cancer in the African Diaspora. In 2006, she established the African-Caribbean Cancer Consortium (AC3), a research group designed to promote collaboration between cancer researchers who focus their work on the African diaspora. This research group supports collaborations in women’s cancers, prostate, upper aero-digestive tract and colorectal cancers. Recognizing the public health significance of cancer in populations of African origin, and socio-cultural factors that influence disparities in health outcomes, she has fostered collaborative research by leading numerous multi-national pooling data initiatives to examine genetic, molecular and environmental contribution in carcinogenesis among populations of African origin. She is the recipient of a number of NIH and Foundation grants and is an American Cancer Society Research Scholar. In 2016 Dr. Ragin received the Cancer Control Award from the American Cancer Society, Greater Philadelphia Area. She is also a recipient of a strategic planning grant from the National Cancer Institute to establish a Caribbean Regional Center for Research Excellence, focused on cancer research in the Caribbean. She is PI of the Cancer Prevention Project of Philadelphia (CAP3) a multicultural community-based cohort consisting of US- and foreign-born persons of African descent. She is also PI of an international cohort in Jamaica which focuses on cancer and CVD risk. Her research program focuses on lung, head and neck, prostate, and cervical cancers.